All
FDA Approves Vizimpro for EGFR-Positive Lung Cancer
September 28th 2018The Food and Drug Administration (FDA) has approved Vizimpro (dacomitinib) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).
Concurrent Tecentriq Adds First Survival Benefit Seen in Small Cell Lung Cancer in 20 Years
September 25th 2018The IMpower133 trial demonstrated the added overall and progression-free survival benefits of adjuvant Tecentriq with standard of care therapy for patients with extensive-stage small cell lung cancer.
Radiation Treatment May Impair Recent Memory in Pediatric Patients With Brain Tumors
September 24th 2018“Key brain regions that we know are typically involved in autobiographical memory formation and retrieval, especially the hippocampus, are located quite far from the primary tumor bed, and thus far from the site of focal radiation,” Sekeres, who is director of the Sekeres Memory Laboratory at Baylor University, said in an interview with CURE.